Home › Clinical › Prehospital Troponin Testing: What ARTICA Showed, What Came Before It, and Where Ambulance Care Goes Next
Clinical

Prehospital Troponin Testing: What ARTICA Showed, What Came Before It, and Where Ambulance Care Goes Next

Prehospital troponin

If you are going to talk seriously about prehospital troponin testing, you have to start with ARTICA. Not because it was the first study to look at troponin in the ambulance, because it was not, but because it was one of the studies that pushed the idea from interesting theory into a real-world ambulance pathway with meaningful patient and system outcomes. That is why it matters.  

The problem it tries to solve is obvious to anyone who works in urgent care. Chest pain drives a huge number of ambulance contacts and emergency department visits, yet most patients do not turn out to have an acute myocardial infarction. The system still has to prove that safely, and that proof usually lives in the emergency department. Prehospital troponin testing asks a simple but uncomfortable question: if the biology belongs to the patient, why does the decision still belong to the building?  

ARTICA: the study that changed the tone of the debate

ARTICA was an investigator-initiated, multicentre, open-label, randomised controlled trial carried out in five ambulance regions in the Netherlands, linked to Radboud University Medical Centre. The trial involved 112 ambulances and 552 ambulance paramedics. It aimed to test a prehospital rule-out strategy in low-risk patients with suspected non-ST-segment elevation acute coronary syndrome using a clinical risk approach plus a single point-of-care troponin measurement.  

The main 2023 trial publication found that the prehospital strategy significantly reduced 30-day healthcare costs, with very low major adverse cardiac event rates in both groups. It also reported that 91.5% of patients in the prehospital rule-out arm were not transferred to the emergency department. That is the result that got people’s attention, and rightly so. It suggests that for a defined low-risk group, ambulance-based troponin testing can reduce unnecessary ED attendance without an obvious early safety signal.  

The 2024 one-year follow-up kept that message alive. It reported that prehospital rule-out with point-of-care troponin in low-risk patients remained cost-effective over a year, with sustained healthcare cost reduction and no sign of a late collapse in safety. That matters because short-term wins are easy to oversell. One-year data are harder to bluff with.  

But here is the part people skip over. ARTICA was not the first prehospital troponin study. The ARTICA protocol itself makes a narrower claim: it describes the trial as the first randomised trial with a primary focus on the cost-effectiveness of a prehospital rule-out strategy for low-risk suspected NSTE-ACS. That wording is important because it is accurate. Calling ARTICA “the first prehospital troponin trial” would be wrong.  

What came before ARTICA

Well before ARTICA, ambulance-based troponin work had already started. A Danish study by Sørensen and colleagues, published in 2011, looked at prehospital Troponin T testing in the diagnosis and triage of patients with suspected acute myocardial infarction. That study focused on feasibility, diagnosis and triage rather than a modern non-conveyance pathway, but it is clear proof that prehospital troponin did not begin with ARTICA.  

There was even earlier work. A 1999 study on prehospital testing for troponin T in patients with suspected acute myocardial infarction reported that a positive prehospital troponin T result seemed to be an objective marker of worse outcome. Again, that is not the same as a contemporary rule-out pathway, but it shows the idea of using troponin before hospital arrival has been around for decades.  

Danish observational work also added an important point in 2019. Rasmussen and colleagues reported that routine prehospital point-of-care cardiac troponin T measurement had high predictive value and could identify high-risk patients even before hospital arrival. That is worth stressing. A lot of the early prehospital troponin literature is at least as much about identifying who is in trouble as it is about proving who is safe to stay away from the hospital.  

The wider evidence after ARTICA

ARTICA is the best-known randomised prehospital pathway trial, but it sits inside a broader evidence base.

In the UK, the PRESTO study, standing for PRe-hospital Evaluation of Sensitive TrOponin, was designed as a multicentre prospective diagnostic accuracy study involving four ambulance services and 12 emergency departments. PRESTO was not a definitive randomised non-conveyance trial like ARTICA. It was designed to test whether decision aids such as T-MACS could be used with prehospital point-of-care troponin to improve early rule-out performance in the ambulance setting. That makes it important, but different.  

Later PRESTO-related analyses continued to build the field. A 2026 secondary analysis evaluated a novel point-of-care high-sensitivity troponin assay within the PRESTO study framework, again in four ambulance services and 12 emergency departments. That tells you the UK evidence base is still developing rather than finished.  

Scotland’s ACCESS study is one of the most useful checks on overconfidence. This prospective EMS cohort study enrolled 1,054 patients with suspected acute coronary syndrome and examined whether HEAR and HEART scores could identify low- and high-risk patients in the out-of-hospital setting. The uncomfortable result was that while paramedics could use the HEAR score for risk discrimination, even adding out-of-hospital point-of-care troponin to calculate HEART scores did not safely rule out 30-day major adverse cardiac events in that cohort. That is a serious warning against pretending that one prehospital troponin plus a score automatically equals safe discharge.  

There has also been Australian pilot work linked to Monash University, looking at paramedic use of the HEART score plus point-of-care troponin for non-traumatic chest pain without ST elevation. The point of that work was feasibility and acceptability, not a final answer on outcomes. Useful, yes. Practice-changing on its own, no.  

LEGEND: not prehospital, but impossible to ignore

Any modern article on this subject also has to mention LEGEND, because it strengthens the biological and pathway argument, even though it was not an ambulance trial. LEGEND was a stepped-wedge cluster randomised controlled trial in four Australian emergency departments from August 2019 to July 2020. It tested whether a strategy using a single high-sensitivity troponin below the assay’s limit of detection, combined with shared decision-making, could safely rule out acute myocardial infarction and reduce emergency department length of stay.  

The answer was yes. LEGEND reported reduced hospital length of stay, more patients safely discharged within four hours, and less cardiac testing, while maintaining safety outcomes in that ED pathway. It does not prove that every ambulance service should immediately start leaving low-risk chest pain patients at home, but it absolutely supports the idea that a single very low troponin can be enough in the right patient, if the surrounding system is good enough.  

So what is the argument for prehospital troponin testing?

The strongest argument is that prehospital troponin testing may allow earlier, smarter decision-making. Not just faster, smarter.

Used well, it could support earlier identification of patients who need urgent cardiac pathways, more proportionate management of low-risk patients, and, in some systems, safe avoidance of unnecessary ED conveyance. The 2026 European Heart Journal Acute Cardiovascular Care review says exactly that: point-of-care high-sensitivity troponin in the ambulance could improve pathways in both ambulance and primary care settings and may be especially valuable where transport times are long or healthcare access is more stretched.  

There is also a system benefit. ARTICA showed cost reduction and fewer unnecessary ED visits. PRESTO and related UK work are trying to refine how these pathways perform in ambulance systems closer to home. Meanwhile, the fact that NIHR opened a 2025 funding call specifically on prehospital cardiac troponin testing to rule out NSTEMI shows that this is no fringe idea. Serious people now see it as a realistic next step in emergency care research.  

And what is the argument against it?

The case against is just as important.

A troponin is not a diagnosis. It helps with myocardial infarction and myocardial injury pathways. It does not safely exclude every dangerous cause of chest pain. Nor does it remove the timing problem in very early presenters. NICE’s existing rule-out guidance is built around emergency department pathways, not routine ambulance-based discharge-at-home decisions. That is not a minor technicality. It is a warning label.  

ACCESS showed that not every prehospital score-plus-troponin combination is safe enough to rule out 30-day major adverse cardiac events. Earlier Danish work is stronger on identifying high-risk patients than proving broad low-risk non-conveyance. Even ARTICA, for all its strengths, was not powered to settle safety once and for all. Its authors said a much larger trial would be needed to prove non-inferiority on MACE properly.  

Then there is governance. This is the real issue. Who owns the decision not to convey? Who defines the inclusion criteria? Who supervises early presenters, ambiguous symptoms, poor historians, abnormal but non-diagnostic ECGs, and patients with competing differentials like pulmonary embolism or aortic pathology? Without a robust clinical framework, prehospital troponin becomes less a clever innovation and more a clever way to move liability into somebody’s living room. That is an inference, but it is strongly supported by the way the evidence is framed across ARTICA, ACCESS, PRESTO and the 2025 to 2026 review literature.  

Where the field seems to be heading

This is still a live research area. A registered TIGER study is looking at high-sensitivity point-of-care troponin I in the prehospital phase, and the UK funding landscape shows clear interest in large-scale research on ambulance-based troponin rule-out pathways. That tells you two things. First, the field has real momentum. Second, the answer is not settled yet.  

Final view

So, where does all this leave us?

ARTICA was not the first study of prehospital troponin testing. Earlier work had already explored feasibility, diagnosis, prognosis and risk stratification in the ambulance setting. What ARTICA did was more specific and more influential. It was one of a number of studies in the field, and the first randomised trial specifically focused on a prehospital troponin-based rule-out strategy for low-risk suspected NSTE-ACS with cost-effectiveness as its primary outcome. That is a strong claim, and it is the right one.  

My blunt read is this: prehospital troponin testing is no longer a gimmick. It has real clinical potential. But it should be seen as a tool for risk stratification and pathway support first, and only as a non-conveyance decision tool when the service has the governance, follow-up and clinical support to use it properly. The science is promising. The temptation to run ahead of the science is real. The smart services will know the difference.  

"The biology belongs to the patient. The question is whether the decision still has to belong to the building."

Evidence & Guidance

Current evidence suggests prehospital troponin testing can improve risk stratification and may reduce unnecessary emergency department conveyance in carefully selected low-risk patients. However, studies such as ACCESS demonstrate that a single troponin result should not yet be considered sufficient on its own to support widespread non-conveyance decisions. Robust governance, validated pathways and further research remain essential.

Quick Overview

  • 8 minute read
  • Intermediate level
  • Updated 5 Oct 2026

Key Learning Points

  • rehospital troponin testing can support earlier risk stratification in suspected ACS.
  • ARTICA demonstrated reduced healthcare costs and fewer unnecessary ED attendances in low-risk patients.
  • ARTICA was not the first prehospital troponin study, but it was the first major randomised trial focused on a prehospital rule-out pathway.
  • Troponin is a tool for assessment, not a diagnosis on its own.
  • Not all score-and-troponin combinations have proven safe for non-conveyance.
  • Early presenters and alternative causes of chest pain remain significant challenges.
YOUR LEARNING

Finished this article?

Mark it as read to record your progress and collect learning points.

Self-reported reading. This does not complete a CPD reflection.
Reading points

Checking your reading progress…